New drug combo for ABO-incompatible kidney transplant
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new drug combination given before a kidney transplant from a living donor with a different blood type. The drugs aim to reduce the immune system's attack on the new kidney, making the transplant safer and more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have end-stage kidney disease (your kidneys have failed) and are on dialysis or have very low kidney function.
- You are scheduled to receive a kidney from a living donor with a different blood type.
- Your blood has a certain level of antibodies against the donor's blood type (at least 1:16).
- You are not allergic to the study drugs, have no active infections, severe heart problems, or other major organ failures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This trial tests a new drug called a BiTE (a type of immunotherapy) to lower very high antibody levels in people waiting for a kidney transplant. If successful, it might help you become eligible for a transplant sooner.
This trial tests a new combination of two chemotherapy drugs (bendamustine and cyclophosphamide) given before a stem cell transplant to help prevent graft-versus-host disease. It is for people with high-risk blood cancers who don't have a fully matched donor and will receive a partially matched transplant.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
Hear when a new ABO Blood Type Incompatible Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.